| Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information. |
| |
| Device | BRACAnalysis CDx |
| Generic Name | Cancer-related germline gene mutation detection system |
| Applicant | Myriad Genetic Laboratories 320 Wakara Way Salt Lake Cit, UT 84108 |
| PMA Number | P140020 |
| Supplement Number | S018 |
| Date Received | 09/21/2018 |
| Decision Date | 12/19/2018 |
| Product Code |
PJG |
| Advisory Committee |
Pathology |
| Clinical Trials | NCT01844986
|
| Supplement Type | Normal 180 Day Track |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval for the BRACAnalysis CDx®, for gBRCA mutated ovarian cancer patients maintenance monotherapy with Lynparza® (olaparib). |
|
|